Zoetis Inc (ZTS) Stock AnalysisZTSStock AnalysisZoetis Inc

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zoetis Inc is currently priced at $77.34, which is below the average analyst price target of $90. However, the stock has seen a significant year-to-date decline of 38.58% and a one-year decline of 49.41%, indicating potential challenges ahead. The RSI is at 56.939, suggesting the stock is neither overbought nor oversold, which supports a cautious approach. Additionally, insider activity is neutral, and hedge funds are increasing their positions by 228.26%, indicating some institutional confidence. The main risk is the lowered revenue forecast for 2026, which now stands at $9.12–$9.32 billion, reflecting ongoing market pressures.

21 analysts cover ZTS: 14 rate it Buy, 7 Hold and 0 Sell. The average price target is 154.20.